COGT · Cogent Biosciences Inc. Common Stock
View on chartInsiders & Stakes
| Fairmount Funds Management LLC Director | ▼ Sell | Open Market | 5,503,418 Shares held | 3/31/2026 | View profile |
| Cole Pinnow Chief Commercial Officer | ▼ Sell | Tax Withholding | 216,650 Shares held | 12/17/2025 | View profile |
| Andrew R. Robbins President and CEO | ▼ Sell | Gift | 160,000 Shares held | 5/19/2026 | View profile |
| John Edward Robinson Chief Scientific Officer | ▼ Sell | Open Market | 140,002 Shares held | 12/26/2025 | View profile |
| Jessica Sachs Chief Medical Officer | ▼ Sell | Open Market | 133,938 Shares held | 12/26/2025 | View profile |
| John L. Green Chief Financial Officer | ▼ Sell | Open Market | 131,834 Shares held | 12/26/2025 | View profile |
| Evan Kearns Chief Legal Officer | ▼ Sell | Open Market | 109,398 Shares held | 12/26/2025 | View profile |
| Arlene Morris | ▼ Sell | Open Market | 0 Shares held | 8/27/2026 | View profile |
Transaction History
| Arlene Morris | ▲ Buy | Option Exercise | 41,927 | $236K | 8/27/2026 |
| Arlene Morris | ▲ Buy | Option Exercise | 3,583 | $9K | 8/27/2026 |
| Arlene Morris | ▼ Sell | Open Market | 3,161 | $119K | 8/27/2026 |
| Arlene Morris | ▼ Sell | Open Market | 42,349 | $1.6M | 8/27/2026 |
| Andrew R. Robbins | ▼ Sell | Gift | 160,000 | $0 | 5/19/2026 |
| Andrew R. Robbins | ▼ Sell | Gift | 160,000 | $0 | 5/19/2026 |
| Fairmount Funds Management LLC | ▼ Sell | Other | 7,000,000 | — | 3/31/2026 |
| Fairmount Funds Management LLC | ▼ Sell | Open Market | 7,000,000 | $242.6M | 3/31/2026 |
| Fairmount Funds Management LLC | ▼ Sell | Open Market | 3,500,000 | $127.4M | 1/22/2026 |
| Evan Kearns | ▼ Sell | Open Market | 65,000 | $2.5M | 12/26/2025 |
| John L. Green | ▼ Sell | Open Market | 77,000 | $3.0M | 12/26/2025 |
| Jessica Sachs | ▼ Sell | Open Market | 82,642 | $3.2M | 12/26/2025 |
| John Edward Robinson | ▼ Sell | Open Market | 90,000 | $3.5M | 12/26/2025 |
| John Edward Robinson | ▲ Buy | Grant | 50,000 | $0 | 12/17/2025 |
| John Edward Robinson | ▲ Buy | Grant | 320,000 | $0 | 12/17/2025 |
| John Edward Robinson | ▼ Sell | Tax Withholding | 139,998 | $5.5M | 12/17/2025 |
| Andrew R. Robbins | ▲ Buy | Grant | 185,000 | $0 | 12/17/2025 |
| Andrew R. Robbins | ▼ Sell | Tax Withholding | 367,497 | $14.5M | 12/17/2025 |
| Cole Pinnow | ▲ Buy | Grant | 50,000 | $0 | 12/17/2025 |
| Cole Pinnow | ▲ Buy | Grant | 214,000 | $0 | 12/17/2025 |
| Evan Kearns | ▼ Sell | Tax Withholding | 125,602 | $5.0M | 12/17/2025 |
| Jessica Sachs | ▲ Buy | Grant | 50,000 | $0 | 12/17/2025 |
| Jessica Sachs | ▲ Buy | Grant | 320,000 | $0 | 12/17/2025 |
| Jessica Sachs | ▼ Sell | Tax Withholding | 154,716 | $6.1M | 12/17/2025 |
| John L. Green | ▲ Buy | Grant | 50,000 | $0 | 12/17/2025 |
| John L. Green | ▲ Buy | Grant | 300,000 | $0 | 12/17/2025 |
| John L. Green | ▼ Sell | Tax Withholding | 145,007 | $5.7M | 12/17/2025 |
| Andrew R. Robbins | ▲ Buy | Grant | 840,000 | $0 | 12/17/2025 |
| Cole Pinnow | ▼ Sell | Tax Withholding | 94,800 | $3.7M | 12/17/2025 |
| Evan Kearns | ▲ Buy | Grant | 40,000 | $0 | 12/17/2025 |
| Evan Kearns | ▲ Buy | Grant | 260,000 | $0 | 12/17/2025 |
| Fairmount Funds Management LLC | ▲ Buy | Open Market | 2,777,777 | $25.0M | 7/10/2025 |
| Cole Pinnow | ▲ Buy | Open Market | 43,750 | $332K | 1/14/2025 |
| Fairmount Funds Management LLC | ▲ Buy | Option Exercise | 1,500,000 | — | 6/10/2024 |
| Fairmount Funds Management LLC | ▼ Sell | Other | 286,851 | — | 3/28/2024 |
| Fairmount Funds Management LLC | ▼ Sell | Other | 286,851 | — | 3/28/2024 |
| Fairmount Funds Management LLC | ▲ Buy | Grant | 1,166,666 | $8.7M | 2/16/2024 |
| Fairmount Funds Management LLC | ▲ Buy | Open Market | 800,000 | $9.6M | 6/9/2023 |
| Jessica Sachs | ▲ Buy | Grant | 622 | $5K | 6/30/2022 |
| Fairmount Funds Management LLC | ▲ Buy | Open Market | 1,200,000 | $9.9M | 6/16/2022 |
| Jessica Sachs | ▲ Buy | Grant | 674 | $5K | 12/31/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Cogent Biosciences: Long-term performance review published
Benzinga published an article analyzing the value of a $1,000 investment in Cogent Biosciences made five years ago. This piece focuses on historical returns rather than new corporate developments or immediate market catalysts. The stock is currently trading near its 52-week low, with technical indicators showing recent downward pressure.
Cogent Biosciences: Long-term performance review published. Benzinga published an article analyzing the value of a $1,000 investment in Cogent Biosciences made five years ago. This piece focuses on historical returns rather than new corporate developments or immediate market catalysts. The stock is currently trading near its 52-week low, with technical indicators showing recent downward pressure.